UK innovation drive told to review the basics, as roll-out uptake is lacking
This article was originally published in Clinica
Executive Summary
Of the 26 action points set out in the UK NHS’s Innovation, Health and Wealth (IHW) programme to boost access to innovative health technologies, only nine had been fully implemented by their September 2012 deadline, according to an official progress review. Moreover, little over a third of providers had discussed the programme at board level and only a quarter had even developed an action plan or timeline for it.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.